Praxis Precision Medicines offers drug development services.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 28, 2020 | Series C | $110M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Ample Plus Fund | — | Series C |